{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T18:06:11Z","timestamp":1776103571960,"version":"3.50.1"},"reference-count":55,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.clml.2024.05.011","type":"journal-article","created":{"date-parts":[[2024,5,14]],"date-time":"2024-05-14T06:53:23Z","timestamp":1715669603000},"page":"821-826","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["SOHO State of the Art Updates and Next Questions | Current Status and Future Directions of Donor Selection"],"prefix":"10.1016","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8532-544X","authenticated-orcid":false,"given":"Rohtesh S.","family":"Mehta","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.clml.2024.05.011_bib0001","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1182\/blood.V98.4.1122","article-title":"Peripheral blood stem cell allograft rejection mediated by CD4(+) T lymphocytes recognizing a single mismatch at HLA-DP beta 1*0901","volume":"98","author":"Fleischhauer","year":"2001","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.clml.2024.05.011_bib0002","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/S1470-2045(12)70004-9","article-title":"Effect of T-cell-epitope matching at HLA-DPB1 in recipients of unrelated-donor haemopoietic-cell transplantation: a retrospective study","volume":"13","author":"Fleischhauer","year":"2012","journal-title":"Lancet Oncol"},{"issue":"6","key":"10.1016\/j.clml.2024.05.011_bib0003","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1182\/blood.2022015708","article-title":"A core group of structurally similar HLA-DPB1 alleles drives permissiveness after hematopoietic cell transplantation","volume":"140","author":"Arrieta-Bolanos","year":"2022","journal-title":"Blood"},{"issue":"24","key":"10.1016\/j.clml.2024.05.011_bib0004","doi-asserted-by":"crossref","first-page":"2712","DOI":"10.1200\/JCO.20.00265","article-title":"Role of HLA-DP expression in graft-versus-host disease after unrelated donor transplantation","volume":"38","author":"Petersdorf","year":"2020","journal-title":"J Clin Oncol"},{"issue":"17","key":"10.1016\/j.clml.2024.05.011_bib0005","doi-asserted-by":"crossref","first-page":"4809","DOI":"10.1182\/bloodadvances.2022009554","article-title":"Assessment of HLA-DPB1 genetic variation using an HLA-DP tool and its implications in clinical transplantation","volume":"7","author":"Sajulga","year":"2023","journal-title":"Blood Adv"},{"issue":"12","key":"10.1016\/j.clml.2024.05.011_bib0006","first-page":"2558","article-title":"Relative impact of HLA matching and non-HLA donor characteristics on outcomes of allogeneic stem cell transplantation for acute myeloid leukemia and myelodysplastic syndrome","volume":"24","author":"Ayuk","year":"2018","journal-title":"Biol BMT"},{"issue":"18","key":"10.1016\/j.clml.2024.05.011_bib0007","doi-asserted-by":"crossref","first-page":"3220","DOI":"10.1182\/blood-2013-02-482547","article-title":"High-resolution HLA matching in hematopoietic stem cell transplantation: a retrospective collaborative analysis","volume":"122","author":"Furst","year":"2013","journal-title":"Blood"},{"issue":"13","key":"10.1016\/j.clml.2024.05.011_bib0008","doi-asserted-by":"crossref","first-page":"4576","DOI":"10.1182\/blood-2007-06-097386","article-title":"High-resolution donor-recipient HLA matching contributes to the success of unrelated donor marrow transplantation","volume":"110","author":"Lee","year":"2007","journal-title":"Blood"},{"issue":"16","key":"10.1016\/j.clml.2024.05.011_bib0009","doi-asserted-by":"crossref","first-page":"2596","DOI":"10.1182\/blood-2014-05-576041","article-title":"Nonpermissive HLA-DPB1 mismatch increases mortality after myeloablative unrelated allogeneic hematopoietic cell transplantation","volume":"124","author":"Pidala","year":"2014","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.clml.2024.05.011_bib0010","doi-asserted-by":"crossref","first-page":"4200","DOI":"10.1182\/blood.V99.11.4200","article-title":"The clinical significance of human leukocyte antigen (HLA) allele compatibility in patients receiving a marrow transplant from serologically HLA-A, HLA-B, and HLA-DR matched unrelated donors","volume":"99","author":"Morishima","year":"2002","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.clml.2024.05.011_bib0011","doi-asserted-by":"crossref","first-page":"e50","DOI":"10.1016\/S2352-3026(19)30208-X","article-title":"Role of HLA-B exon 1 in graft-versus-host disease after unrelated haemopoietic cell transplantation: a retrospective cohort study","volume":"7","author":"Petersdorf","year":"2020","journal-title":"Lancet Haematol"},{"issue":"26","key":"10.1016\/j.clml.2024.05.011_bib0012","doi-asserted-by":"crossref","first-page":"3996","DOI":"10.1182\/blood-2014-09-599969","article-title":"HLA-C expression levels define permissible mismatches in hematopoietic cell transplantation","volume":"124","author":"Petersdorf","year":"2014","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.clml.2024.05.011_bib0013","doi-asserted-by":"crossref","first-page":"S21","DOI":"10.1016\/j.jtct.2023.12.063","article-title":"HLA mismatching and transplant outcome in the ptcy era: a comprehensive study by the EBMT cellular therapy and immunobiology working party","volume":"30","author":"Bola\u00f1os","year":"2024","journal-title":"Transplantation and Cellular Therapy"},{"issue":"12","key":"10.1016\/j.clml.2024.05.011_bib0014","doi-asserted-by":"crossref","first-page":"3687","DOI":"10.1002\/1521-4141(200112)31:12<3687::AID-IMMU3687>3.0.CO;2-C","article-title":"The analysis of the natural killer-like activity of human cytolytic T lymphocytes revealed HLA-E as a novel target for TCR alpha\/beta-mediated recognition","volume":"31","author":"Pietra","year":"2001","journal-title":"Eur J Immunol"},{"issue":"5","key":"10.1016\/j.clml.2024.05.011_bib0015","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1084\/jem.187.5.813","article-title":"Recognition of human histocompatibility leukocyte antigen (HLA)-E complexed with HLA class I signal sequence-derived peptides by CD94\/NKG2 confers protection from natural killer cell-mediated lysis","volume":"187","author":"Borrego","year":"1998","journal-title":"J Exp Med"},{"issue":"12","key":"10.1016\/j.clml.2024.05.011_bib0016","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1093\/infdis\/jis275","article-title":"HLA-B signal peptide polymorphism influences the rate of HIV-1 acquisition but not viral load","volume":"205","author":"Merino","year":"2012","journal-title":"J Infect Dis"},{"issue":"5","key":"10.1016\/j.clml.2024.05.011_bib0017","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1002\/eji.1830270517","article-title":"The human major histocompatibility complex class Ib molecule HLA-E binds signal sequence-derived peptides with primary anchor residues at positions 2 and 9","volume":"27","author":"Braud","year":"1997","journal-title":"Eur J Immunol"},{"issue":"3","key":"10.1016\/j.clml.2024.05.011_bib0018","first-page":"362","article-title":"HLA-B leader and survivorship after HLA-mismatched unrelated donor transplantation","volume":"136","author":"Petersdorf","year":"2020","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.clml.2024.05.011_bib0019","first-page":"270","article-title":"Assessment of HLA-B genetic variation with an HLA-B leader tool and implications in clinical transplantation","volume":"6","author":"Sajulga","year":"2022","journal-title":"Blood Adv"},{"issue":"13","key":"10.1016\/j.clml.2024.05.011_bib0020","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1200\/JCO.22.01229","article-title":"Impact of the HLA immunopeptidome on survival of leukemia patients after unrelated donor transplantation","volume":"41","author":"Crivello","year":"2023","journal-title":"J Clin Oncol"},{"issue":"25","key":"10.1016\/j.clml.2024.05.011_bib0021","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.1056\/NEJMoa2215943","article-title":"Post-transplantation cyclophosphamide-based graft-versus-host disease prophylaxis","volume":"388","author":"Bolanos-Meade","year":"2023","journal-title":"N Engl J Med"},{"issue":"17","key":"10.1016\/j.clml.2024.05.011_bib0022","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1200\/JCO.20.01086","article-title":"Phase II trial of costimulation blockade with abatacept for prevention of acute GVHD","volume":"39","author":"Watkins","year":"2021","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.clml.2024.05.011_bib0023","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1182\/blood.2021013443","article-title":"HLA informs risk predictions after haploidentical stem cell transplantation with posttransplantation cyclophosphamide","volume":"139","author":"Fuchs","year":"2022","journal-title":"Blood"},{"issue":"20","key":"10.1016\/j.clml.2024.05.011_bib0024","doi-asserted-by":"crossref","first-page":"4031","DOI":"10.1182\/bloodadvances.2021004862","article-title":"Treatment of allosensitized patients receiving allogeneic transplantation","volume":"5","author":"Ciurea","year":"2021","journal-title":"Blood Adv"},{"key":"10.1016\/j.clml.2024.05.011_bib0025","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1165759","article-title":"Results of haploidentical transplant in patients with donor-specific antibodies: a survey on behalf of the Spanish Group of Hematopoietic Transplant and Cell Therapy","volume":"14","author":"Bailen","year":"2023","journal-title":"Front Immunol"},{"issue":"10","key":"10.1016\/j.clml.2024.05.011_bib0026","doi-asserted-by":"crossref","first-page":"3611","DOI":"10.1182\/blood-2006-04-017467","article-title":"Humoral immunity is the dominant barrier for allogeneic bone marrow engraftment in sensitized recipients","volume":"108","author":"Xu","year":"2006","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.clml.2024.05.011_bib0027","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1182\/blood-2006-05-022772","article-title":"Preformed antibody, not primed T cells, is the initial and major barrier to bone marrow engraftment in allosensitized recipients","volume":"109","author":"Taylor","year":"2007","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.clml.2024.05.011_bib0028","first-page":"1392","article-title":"Complement-binding donor-specific anti-hla antibodies and risk of primary graft failure in hematopoietic stem cell transplantation","volume":"21","author":"Ciurea","year":"2015","journal-title":"Biol BMT"},{"issue":"7","key":"10.1016\/j.clml.2024.05.011_bib0029","doi-asserted-by":"crossref","first-page":"e23261","DOI":"10.1002\/jcla.23261","article-title":"Combination treatment of rituximab and donor platelets infusion to reduce donor-specific anti-HLA antibodies for stem cells engraftment in haploidentical transplantation","volume":"34","author":"Zhang","year":"2020","journal-title":"J Clin Lab Anal"},{"issue":"4","key":"10.1016\/j.clml.2024.05.011_bib0030","first-page":"508","article-title":"Risk and prevention of graft failure in patients with preexisting donor-specific HLA antibodies undergoing unmanipulated haploidentical SCT","volume":"47","author":"Yoshihara","year":"2012","journal-title":"BMT"},{"issue":"6","key":"10.1016\/j.clml.2024.05.011_bib0031","first-page":"751","article-title":"Donor HLA-specific abs: to BMT or not to BMT?","volume":"50","author":"Leffell","year":"2015","journal-title":"BMT"},{"issue":"5","key":"10.1016\/j.clml.2024.05.011_bib0032","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1002\/ajh.26870","article-title":"Younger haploidentical donor versus older matched unrelated donor for patients with AML\/MDS","volume":"98","author":"Marcoux","year":"2023","journal-title":"Am J Hematol"},{"issue":"8","key":"10.1016\/j.clml.2024.05.011_bib0033","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1182\/bloodadvances.2022009240","article-title":"Haploidentical vs matched unrelated donors for patients with ALL: donor age matters more than donor type","volume":"7","author":"Mehta","year":"2023","journal-title":"Blood Adv"},{"issue":"14","key":"10.1016\/j.clml.2024.05.011_bib0034","doi-asserted-by":"crossref","first-page":"4335","DOI":"10.1182\/bloodadvances.2022007741","article-title":"HLA-matching with PTCy: a reanalysis of a CIBMTR dataset with propensity score matching and donor age","volume":"6","author":"Ambinder","year":"2022","journal-title":"Blood Adv"},{"issue":"6","key":"10.1016\/j.clml.2024.05.011_bib0035","doi-asserted-by":"crossref","first-page":"377.e1","DOI":"10.1016\/j.jtct.2023.03.028","article-title":"Impact of donor age in haploidentical-post-transplantation cyclophosphamide versus matched unrelated donor post-transplantation cyclophosphamide hematopoietic stem cell transplantation in patients with acute myeloid leukemia","volume":"29","author":"Mehta","year":"2023","journal-title":"Transplant Cell Ther"},{"issue":"9","key":"10.1016\/j.clml.2024.05.011_bib0036","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.1182\/bloodadvances.2024012669","article-title":"Combined effect of unrelated donor age and HLA peptide-binding motifs (PBM) match status on HCT outcomes","volume":"8","author":"Mehta","year":"2024","journal-title":"Blood Adv"},{"issue":"13","key":"10.1016\/j.clml.2024.05.011_bib0037","doi-asserted-by":"crossref","first-page":"2567","DOI":"10.1182\/blood-2012-08-453860","article-title":"Who is the better donor for older hematopoietic transplant recipients: an older-aged sibling or a young, matched unrelated volunteer?","volume":"121","author":"Alousi","year":"2013","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.clml.2024.05.011_bib0038","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1001\/jamaoncol.2021.6846","article-title":"Relapse and disease-free survival in patients with myelodysplastic syndrome undergoing allogeneic hematopoietic cell transplantation using older matched sibling donors vs younger matched unrelated donors","volume":"8","author":"Guru Murthy","year":"2022","journal-title":"JAMA Oncol"},{"issue":"5","key":"10.1016\/j.clml.2024.05.011_bib0039","first-page":"1049","article-title":"Development of an unrelated donor selection score predictive of survival after HCT: donor age matters most","volume":"24","author":"Shaw","year":"2018","journal-title":"Biol BMT"},{"issue":"2","key":"10.1016\/j.clml.2024.05.011_bib0040","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1182\/blood-2015-08-663823","article-title":"The effect of donor characteristics on survival after unrelated donor transplantation for hematologic malignancy","volume":"127","author":"Kollman","year":"2016","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.clml.2024.05.011_bib0041","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1038\/leu.2012.210","article-title":"Allogeneic stem cell transplantation for older advanced MDS patients: improved survival with young unrelated donor in comparison with HLA-identical siblings","volume":"27","author":"Kroger","year":"2013","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.clml.2024.05.011_bib0042","first-page":"33","article-title":"Donor age and degree of HLA matching have a major impact on the outcome of unrelated donor haematopoietic cell transplantation for chronic myeloid leukaemia","volume":"37","author":"Carreras","year":"2006","journal-title":"BMT"},{"issue":"7","key":"10.1016\/j.clml.2024.05.011_bib0043","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.1182\/blood.V98.7.2043","article-title":"Donor characteristics as risk factors in recipients after transplantation of bone marrow from unrelated donors: the effect of donor age","volume":"98","author":"Kollman","year":"2001","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.clml.2024.05.011_bib0044","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/j.jtct.2023.07.015","article-title":"Younger matched unrelated donors confer decreased relapse risk compared to older sibling donors in older patients with b cell acute lymphoblastic leukemia undergoing allogeneic hematopoietic cell transplantation","volume":"29","author":"Abid","year":"2023","journal-title":"Transplant Cell Ther"},{"issue":"16","key":"10.1016\/j.clml.2024.05.011_bib0045","doi-asserted-by":"crossref","first-page":"3900","DOI":"10.1182\/bloodadvances.2020001620","article-title":"Impact of donor age and kinship on clinical outcomes after T-cell-replete haploidentical transplantation with PT-Cy","volume":"4","author":"Mariotti","year":"2020","journal-title":"Blood Adv"},{"issue":"5","key":"10.1016\/j.clml.2024.05.011_bib0046","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1182\/bloodadvances.2020003922","article-title":"Relationship of donor age and relationship to outcomes of haploidentical transplantation with posttransplant cyclophosphamide","volume":"5","author":"DeZern","year":"2021","journal-title":"Blood Adv"},{"issue":"3","key":"10.1016\/j.clml.2024.05.011_bib0047","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1182\/bloodadvances.2017014829","article-title":"Effect of donor characteristics on haploidentical transplantation with posttransplantation cyclophosphamide","volume":"2","author":"McCurdy","year":"2018","journal-title":"Blood Adv"},{"issue":"3","key":"10.1016\/j.clml.2024.05.011_bib0048","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.jtct.2022.11.027","article-title":"HLA factors versus non-HLA factors for haploidentical donor selection","volume":"29","author":"Mehta","year":"2023","journal-title":"Transplant Cell Ther"},{"issue":"3","key":"10.1016\/j.clml.2024.05.011_bib0049","doi-asserted-by":"crossref","first-page":"169.e1","DOI":"10.1016\/j.jtct.2021.12.014","article-title":"Risk factors for early cytomegalovirus reactivation and impact of early cytomegalovirus reactivation on clinical outcomes after t cell-replete haploidentical transplantation with post-transplantation cyclophosphamide","volume":"28","author":"Mariotti","year":"2022","journal-title":"Transplant Cell Ther"},{"issue":"4","key":"10.1016\/j.clml.2024.05.011_bib0050","first-page":"422","article-title":"Comparable survival using a CMV-matched or a mismatched donor for CMV+ patients undergoing T-replete haplo-HSCT with PT-Cy for acute leukemia: a study of behalf of the infectious diseases and acute leukemia working parties of the EBMT","volume":"53","author":"Cesaro","year":"2018","journal-title":"BMT"},{"issue":"23","key":"10.1016\/j.clml.2024.05.011_bib0051","doi-asserted-by":"crossref","first-page":"3291","DOI":"10.1182\/blood.2020009362","article-title":"Posttransplant cyclophosphamide is associated with increased cytomegalovirus infection: a CIBMTR analysis","volume":"137","author":"Goldsmith","year":"2021","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.clml.2024.05.011_bib0052","first-page":"746","article-title":"ABO mismatch is associated with increased nonrelapse mortality after allogeneic hematopoietic cell transplantation","volume":"21","author":"Logan","year":"2015","journal-title":"Biol BMT"},{"issue":"4","key":"10.1016\/j.clml.2024.05.011_bib0053","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1002\/ajh.26834","article-title":"Association of ABO mismatch with the outcomes of allogeneic hematopoietic cell transplantation for acute leukemia","volume":"98","author":"Guru Murthy","year":"2023","journal-title":"Am J Hematol"},{"issue":"8","key":"10.1016\/j.clml.2024.05.011_bib0054","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1002\/ajh.24771","article-title":"ABO incompatibility in mismatched unrelated donor allogeneic hematopoietic cell transplantation for acute myeloid leukemia: a report from the Acute Leukemia Working Party of the EBMT","volume":"92","author":"Canaani","year":"2017","journal-title":"Am J Hematol"},{"issue":"6","key":"10.1016\/j.clml.2024.05.011_bib0055","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.3324\/haematol.2016.160804","article-title":"Impact of ABO incompatibility on patients' outcome after haploidentical hematopoietic stem cell transplantation for acute myeloid leukemia: a report from the Acute Leukemia Working Party of the EBMT","volume":"102","author":"Canaani","year":"2017","journal-title":"Haematologica"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265024001836?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265024001836?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,25]],"date-time":"2024-11-25T12:47:43Z","timestamp":1732538863000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265024001836"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":55,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["S2152265024001836"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2024.05.011","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"SOHO State of the Art Updates and Next Questions | Current Status and Future Directions of Donor Selection","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2024.05.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}